KR102652375B1 - Method for producing magnesium tripeptide-1 - Google Patents
Method for producing magnesium tripeptide-1 Download PDFInfo
- Publication number
- KR102652375B1 KR102652375B1 KR1020240005910A KR20240005910A KR102652375B1 KR 102652375 B1 KR102652375 B1 KR 102652375B1 KR 1020240005910 A KR1020240005910 A KR 1020240005910A KR 20240005910 A KR20240005910 A KR 20240005910A KR 102652375 B1 KR102652375 B1 KR 102652375B1
- Authority
- KR
- South Korea
- Prior art keywords
- tripeptide
- magnesium
- reaction
- arginine
- aqueous solution
- Prior art date
Links
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 title claims abstract description 115
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 88
- 239000011777 magnesium Substances 0.000 title claims abstract description 88
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 46
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 46
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000008569 process Effects 0.000 claims abstract description 22
- 238000003756 stirring Methods 0.000 claims abstract description 22
- 239000007864 aqueous solution Substances 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims abstract description 17
- 229960002223 arginine aspartate Drugs 0.000 claims abstract description 17
- 239000008213 purified water Substances 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 14
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 10
- 229930064664 L-arginine Natural products 0.000 claims abstract description 10
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 10
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 10
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 7
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 7
- 230000003020 moisturizing effect Effects 0.000 abstract description 27
- 210000002615 epidermis Anatomy 0.000 abstract description 8
- 230000008591 skin barrier function Effects 0.000 abstract description 6
- 238000001704 evaporation Methods 0.000 abstract description 4
- 230000008020 evaporation Effects 0.000 abstract description 4
- 229910052751 metal Inorganic materials 0.000 abstract description 4
- 239000002184 metal Substances 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 238000006482 condensation reaction Methods 0.000 abstract description 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 40
- 239000000203 mixture Substances 0.000 description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- 239000002537 cosmetic Substances 0.000 description 20
- 239000004909 Moisturizer Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000001333 moisturizer Effects 0.000 description 19
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 16
- 239000003995 emulsifying agent Substances 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 11
- 230000003750 conditioning effect Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 229940058015 1,3-butylene glycol Drugs 0.000 description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- 229940015975 1,2-hexanediol Drugs 0.000 description 7
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 4
- 241000208467 Macadamia Species 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 235000014104 aloe vera supplement Nutrition 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229960004246 arginine glutamate Drugs 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 229940081733 cetearyl alcohol Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940100524 ethylhexylglycerin Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940104261 taurate Drugs 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 2
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000010464 refined olive oil Substances 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 마그네슘트라이펩타이드-1의 제조방법에 관한 것이다. 보다 상세하게는, L-아르기닌/L(+)-아스파트산/L-글루탐산으로 형성된 트라이펩타이드 및 마그네슘의 축합반응으로 합성된 트라이펩타이드 금속염으로써 피부장벽 내부 및 표면에서 표피층 내부수분의 증발 방지 및 표피층 표면 수분의 유지 특성의 강력한 보습작용을 수행할 수 있는 마그네슘트라이펩타이드-1의 제조방법에 관한 것이다.
이를 위해 본 발명은 (a) L-아르기닌을 정제수에 상온에서 완전 용해시킨 후 L(+)-아스파트산을 가하여 가열 교반하여 펩타이드 반응을 수행하여 알지닌아스파테이트 수용액을 수득하는 제1 합성과정, 제1 합성과정을 거쳐 수득된 알지닌아스파테이트 수용액에 L-글루탐산을 가하고 가열 교반하여 펩타이드 반응을 수행하여 트라이펩타이드-1 수용액을 수득하는 제2 과정을 포함하는 트라이펩타이드-1 합성과정; (b) 트라이펩타이드-1 합성단계를 거쳐 반응종료된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 가열 교반하여 마그네슘트라이펩타이드-1 수용액을 수득하는 마그네슘트라이펩타이드-1 합성단계를 포함하는 마그네슘트라이펩타이드-1의 제조방법을 제공한다.The present invention relates to a method for producing magnesium tripeptide-1. More specifically, it is a tripeptide metal salt synthesized through the condensation reaction of magnesium and tripeptide formed from L-arginine/L(+)-aspartic acid/L-glutamic acid, preventing evaporation of moisture inside the epidermal layer from inside and on the skin barrier and on the surface. It relates to a method for producing magnesium tripeptide-1, which can perform a strong moisturizing effect by maintaining moisture on the surface of the epidermal layer.
For this purpose, the present invention involves (a) a first synthesis process in which L-arginine is completely dissolved in purified water at room temperature, then L(+)-aspartic acid is added, heated and stirred to perform a peptide reaction to obtain an aqueous arginine aspartate solution; , a tripeptide-1 synthesis process including a second process of adding L-glutamic acid to the arginine aspartate aqueous solution obtained through the first synthesis process and heating and stirring to perform a peptide reaction to obtain an aqueous tripeptide-1 solution; (b) Magnesium tripeptide-1 synthesis step of adding magnesium hydroxide to the tripeptide-1 aqueous solution that has completed the reaction through the tripeptide-1 synthesis step and heating and stirring to obtain a magnesium tripeptide-1 aqueous solution. A method for producing peptide-1 is provided.
Description
본 발명은 마그네슘트라이펩타이드-1의 제조방법에 관한 것이다. 보다 상세하게는, L-아르기닌/L(+)-아스파트산/L-글루탐산으로 형성된 트라이펩타이드 및 마그네슘의 축합반응으로 합성된 트라이펩타이드 금속염으로써 피부장벽 내부 및 표면에서 표피층 내부수분의 증발 방지 및 표피층 표면 수분의 유지 특성의 강력한 보습작용을 수행할 수 있는 마그네슘트라이펩타이드-1의 제조방법에 관한 것이다.The present invention relates to a method for producing magnesium tripeptide-1. More specifically, it is a tripeptide metal salt synthesized through the condensation reaction of magnesium and tripeptide formed from L-arginine/L(+)-aspartic acid/L-glutamic acid, preventing evaporation of moisture inside the epidermal layer from inside and on the skin barrier and on the surface. It relates to a method for producing magnesium tripeptide-1, which can perform a strong moisturizing effect by maintaining moisture on the surface of the epidermal layer.
피부는 인체의 최외곽에서 보호막으로서의 기능을 수행하며 물과 전해질 등의 생체성분의 손실을 방지함과 동시에 외부 유해 물질의 생체 내 유입을 차단하는 중요한 기능을 수행하고 있다. 특히, 각질층은 피부 최외곽층을 형성하여 건조한 외부환경으로부터 피부 내부의 수분 손실을 막아주는 중요한 역할을 수행하고 있으며, 그와 동시에 그 자신도 적당한 수분을 보유하여 유연성 내지 탄력성을 보이게 된다. The skin functions as a protective layer at the outermost layer of the human body and performs an important function of preventing the loss of biological components such as water and electrolytes and at the same time blocking the inflow of external harmful substances into the body. In particular, the stratum corneum forms the outermost layer of the skin and plays an important role in preventing moisture loss inside the skin from a dry external environment. At the same time, the stratum corneum itself retains adequate moisture and exhibits flexibility and elasticity.
정상적인 피부의 각질층에는 보통 10% 이상의 수분이 함유되어 탄력성과 유연성을 지니게 된다. 물의 함유 정도는 피부 부위 별로 살펴보면 깊은 진피에서 표면의 표피로 갈수록 감소한다. 각질층은 약 물 15%, 단백질 70% 및 지질 15%로 구성되어 있는 반면, 진피층 특히 각질형성 세포의 경우 물 70%, 단백질 15% 및 지질 5%로 구성된다. The stratum corneum of normal skin usually contains more than 10% moisture, making it elastic and flexible. When looking at each skin area, the level of water content decreases from the deep dermis to the surface epidermis. The stratum corneum is composed of approximately 15% water, 70% protein, and 15% lipid, while the dermal layer, especially keratinocytes, is composed of 70% water, 15% protein, and 5% lipid.
각질세포가 표면에 가까워질수록 수분함량은 점점 감소하여 결국 5~10%에 이르게 된다. 아무리 좋은 피부라 할지라도 최외곽의 피부는 20% 이상의 물이 함유되어 있지는 않다. 보통 촉촉한 피부라 일컫는 피부의 각질층 수분량은 15% 내외이다. As keratinocytes get closer to the surface, the moisture content gradually decreases, eventually reaching 5 to 10%. No matter how good your skin is, the outermost skin does not contain more than 20% water. The moisture content of the stratum corneum of skin, which is commonly referred to as moist skin, is around 15%.
그러나, 노화, 호르몬 분비 변화, 바람, 기온 및 햇빛 등과 같은 외부 환경, 세안 및 면도 등과 같은 물리적 인자 등의 여러 요인에 의해 피부는 수분 균형을 잃게 되어 각질층의 수분 함량이 10% 이하인 건성피부가 되기 쉽다. 이로 인해 피부의 탄력성 및 유연성이 소실되며, 궁극적으로 피부의 보호기능이 사라져 피부 갈라짐, 홍반, 가려움증 등이 유발되고, 더 심해지면, 건선, 아토피 등의 피부질환이 발생하게 된다. However, due to various factors such as aging, changes in hormonal secretion, external environment such as wind, temperature and sunlight, and physical factors such as washing and shaving, the skin loses its moisture balance, resulting in dry skin with the moisture content of the stratum corneum below 10%. easy. As a result, the skin's elasticity and flexibility are lost, and ultimately the skin's protective function is lost, causing skin cracking, erythema, and itching. If it gets worse, skin diseases such as psoriasis and atopic dermatitis occur.
따라서, 외부 환경이 건조하면, 피부의 수분 보유 능력과 수분 증발 억제 능력을 보완해서 피부를 부드럽고 촉촉하게 해 주어야 하며, 이와 같은 기능을 지닌 보습제 화장품에 대한 관심이 점점 높아지게 되었다. Therefore, when the external environment is dry, the skin's moisture retention ability and moisture evaporation inhibition ability must be supplemented to make the skin soft and moist, and interest in moisturizing cosmetics with such functions has increased.
보습제(moisturizer)는 단순한 피부 수분 보충 뿐만 아니라, 피부의 가장 중요한 기능 중 하나인 피부 장벽 기능 회복에 많은 관심이 집중되고 있으며, 2가지로 구분되어 사용되고 있다. Moisturizers are receiving a lot of attention not only for simply replenishing skin moisture, but also for restoring skin barrier function, which is one of the most important functions of the skin, and are used in two types.
첫 번째, 천연보습인자(NMF, Natural Moisturizing Factor) 성분인 아미노산, 젖산 나트륨(sodium lactate), 피로리돈 카르복시산 나트륨(sodium PCA), 요소(urea) 등과 같은 화합물들이다. First, they are natural moisturizing factor (NMF) compounds such as amino acids, sodium lactate, sodium pyrolidone carboxylate (sodium PCA), and urea.
두 번째, 높은 함수율을 나타내는 글리세린, 하이아루론산, 폴리에틸렌글리콜 등과 같은 고분자 화합물이다. 이와 같은 고분자 성분은 분자량이 크기 때문에 표피에 사용할 경우에는 전혀 흡수되지 않고, 색조나 썬크림을 사용할 경우 화장을 들뜨게 하는 단점을 가지고 있다. Second, it is a high molecular compound such as glycerin, hyaluronic acid, polyethylene glycol, etc. that exhibits a high moisture content. Because these polymer ingredients have a high molecular weight, they are not absorbed at all when used on the epidermis, and have the disadvantage of causing makeup to flake when used with color tone or sunscreen.
또한, 피부 수분 함량이 공기 중의 수분 함량보다 높을 경우 히알루론산의 수분 함유 성질로 인하여, 공기 중에 수분을 빼앗기게 되어 오히려 피부가 건조해지게 되는 문제점을 지니고 있다. In addition, when the skin moisture content is higher than the moisture content in the air, due to the moisture-containing nature of hyaluronic acid, moisture is lost in the air, which causes the skin to become dry.
한편, 아토피피부염, 건선 등의 피부질환 환자와 건조하거나 과각화된 피부의 각질에서는 천연보습인자(NMF, Natural Moisturizing Factor)의 구성성분인 아미노산의 양이 비정상적으로 감소되어 있음이 보고된다. Meanwhile, it is reported that the amount of amino acids, a component of natural moisturizing factor (NMF), is abnormally reduced in patients with skin diseases such as atopic dermatitis and psoriasis and in dead skin cells with dry or hyperkeratinized skin.
또한, 필라그린의 유전적 기능손상은 각질 중 아미노산 양의 감소와 밀접하게 관련되어 있으며 아미노산이 피부의 보습상태에 중요한 역할을 한다는 연구가 다수 보고되었다. In addition, many studies have reported that genetic dysfunction of filaggrin is closely related to a decrease in the amount of amino acids in keratin, and that amino acids play an important role in the moisturizing condition of the skin.
그 외, 각질층 아미노산 양을 측정하여 각질층 수분상태와 아미노산 양 사이의 관계를 관찰하고 필라그린 면역반응성 연구를 통해 아미노산이 감소되면 피부가 건조된다는 보고와 염기성 아미노산과 같은 천연보습인자(NMF, Natural Moisturizing Factor) 성분이 각질의 유연성을 유지하는 데 중요한 성분이라는 연구가 보고되기도 하였다. In addition, the amount of amino acids in the stratum corneum was measured to observe the relationship between the moisture status of the stratum corneum and the amount of amino acids. Through a study on filaggrin immunoreactivity, it was reported that the skin dries when amino acids are reduced, and natural moisturizing factors (NMF, Natural Moisturizing Factors) such as basic amino acids. Research has also reported that the ingredient (Factor) is an important ingredient in maintaining the flexibility of keratin.
한편, 현재까지 피부 보습 향상을 위한 화장품으로는 다가알코올, 폴리올, 당류 등의 보습원료를 주로 이용하여 왔으나, 보습 효능 강화를 위해 고농도의 배합 시 끈적임, 경피 자극, 제형안정성 확보의 어려움 등의 문제점 등을 나타내며, 이의 극복을 위한 대체 원료들로써 여러 가지 천연 유래 추출물 및 각종 단백질 분해물을 이용한 보습제 개발이 진행되었으나, 아직도 그 효과가 미비하며, 고농도로 사용해야 하는 많은 어려움을 가지고 있다. Meanwhile, to date, cosmetics to improve skin moisturization have mainly used moisturizing raw materials such as polyhydric alcohols, polyols, and sugars, but problems such as stickiness, dermal irritation, and difficulty in securing formulation stability when mixed at high concentrations to enhance moisturizing effect. In order to overcome this problem, the development of moisturizers using various natural extracts and various protein decomposition products has been developed as alternative raw materials, but their effectiveness is still insufficient and there are many difficulties in using them in high concentrations.
선행기술문헌 : KR 등록특허공보 제10-1507090호(2015.4.1.공고)Prior art literature: KR Registered Patent Publication No. 10-1507090 (announced on April 1, 2015)
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로, 상기 기술된 현존하는 화학적 보습제 및 천연물 유래 보습제의 문제점을 개선하기 위해 고안된 기술로서, 펩타이드를 골격으로 하는 금속염 피막형성 보습제로서, 피부 장벽 내부 및 표면에서 표피층 내부 수분의 증발 방지 및 표피층 표면 수분에 대한 유지 특성의 강력한 보습작용을 수행할 수 있는 마그네슘트라이펩타이드-1의 제조방법을 제공하는 데 그 목적이 있다. The present invention was devised to solve the above problems, and is a technology designed to improve the problems of existing chemical moisturizers and natural product-derived moisturizers described above. It is a metal salt film-forming moisturizer with peptide as the skeleton, and is a moisturizer that forms a film inside the skin barrier. The purpose is to provide a method for producing magnesium tripeptide-1, which can perform a strong moisturizing effect by preventing evaporation of moisture inside the epidermal layer from the surface and retaining moisture on the surface of the epidermal layer.
상기 목적을 달성하기 위해 안출된 본 발명에 따른 마그네슘트라이펩타이드-1의 제조방법은 (a) L-아르기닌을 정제수에 상온에서 완전 용해시킨 후 L(+)-아스파트산을 가하여 가열 교반하여 펩타이드 반응을 수행하여 알지닌아스파테이트 수용액을 수득하는 제1 합성과정, 제1 합성과정을 거쳐 수득된 알지닌아스파테이트 수용액에 L-글루탐산을 가하고 가열 교반하여 펩타이드 반응을 수행하여 트라이펩타이드-1 수용액을 수득하는 제2 과정을 포함하는 트라이펩타이드-1 합성과정; (b) 트라이펩타이드-1 합성단계를 거쳐 반응종료된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 가열 교반하여 마그네슘트라이펩타이드-1 수용액을 수득하는 마그네슘트라이펩타이드-1 합성단계 포함한다. The method for producing magnesium tripeptide-1 according to the present invention devised to achieve the above object is (a) completely dissolving L-arginine in purified water at room temperature, adding L(+)-aspartic acid, heating and stirring, and forming the peptide. A first synthesis process of performing a reaction to obtain an aqueous arginine aspartate solution. Adding L-glutamic acid to the aqueous solution of arginine aspartate obtained through the first synthesis process and heating and stirring to perform a peptide reaction to obtain an aqueous solution of tripeptide-1. Tripeptide-1 synthesis process including a second process to obtain; (b) It includes a magnesium tripeptide-1 synthesis step of adding magnesium hydroxide to the tripeptide-1 aqueous solution that has completed the reaction through the tripeptide-1 synthesis step, heating and stirring to obtain a magnesium tripeptide-1 aqueous solution.
또한, (a) 단계에서는 제1 합성과정에서 L-아르기닌을 정제수에 상온에서 완전 용해시킨 후 L(+)-아스파트산을 가하여 40℃에서 10분 간 가열 교반하여 펩타이드 반응을 수행하고, 제2 합성과정에서는 제1 합성과정을 거쳐 수득된 알지닌아스파테이트 수용액에 L-글루탐산을 가하고 60℃에서 30분 간 가열 교반하여 펩타이드 반응을 수행하는 것을 포함한다. In addition, in step (a), in the first synthesis process, L-arginine was completely dissolved in purified water at room temperature, then L(+)-aspartic acid was added and heated and stirred at 40°C for 10 minutes to perform a peptide reaction, 2 The synthesis process involves adding L-glutamic acid to the arginine aspartate aqueous solution obtained through the first synthesis process and heating and stirring at 60°C for 30 minutes to perform a peptide reaction.
또한, (b) 단계에서는 상기 (a) 단계를 거쳐 수득된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 55℃~100℃ 에서 30분~60분 간 가열 교반하는 것을 특징으로 한다. Additionally, in step (b), magnesium hydroxide is added to the aqueous solution of tripeptide-1 obtained through step (a), and the mixture is heated and stirred at 55°C to 100°C for 30 to 60 minutes.
본 발명에 의하면 펩타이드 유래 피부보호막 형성제로써 신규한 화장품 원료를 제공할 수 있도록 하는 효과가 있다. According to the present invention, it has the effect of providing a new cosmetic raw material as a peptide-derived skin protective film forming agent.
또한, 본 발명에 의하면 마그네슘트라이펩타이드-1은 펩타이드 금속염 형태로서 펩타이드 잔여 아민기에 의한 피부 자극 완화 효과를 기대할 수 있다. In addition, according to the present invention, magnesium tripeptide-1 is in the form of a peptide metal salt and can be expected to have an effect of alleviating skin irritation due to the residual amine group of the peptide.
또한, 본 발명에 의하면 아미노산 유래 아민취 감소 효과를 기대할 수 있다.In addition, according to the present invention, the effect of reducing amino acid-derived amine odor can be expected.
또한, 본 발명에 의하면 화장품 조성 내 기타 피부보습제와 동반 사용 시 피부 밀착감을 증대시킬 수 있어 보습 유지력을 향상시킬 수 있도록 하는 효과가 있다. In addition, according to the present invention, when used together with other skin moisturizers in cosmetic compositions, it is possible to increase skin adhesion, which has the effect of improving moisture retention.
또한, 본 발명에 의하면 피부진정, 피부장벽 강화, 경피수분손실량 감소, 손상 각질층의 정상화 등의 효과를 기대할 수 있다. In addition, according to the present invention, effects such as skin soothing, strengthening the skin barrier, reducing transepidermal water loss, and normalizing the damaged stratum corneum can be expected.
도 1은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1 제조방법의 순서도,
도 2 내지 도 4는 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 분자구조 분석을 위해 NMR 분석과 작용기 결합여부 확인을 위한 IR 분석을 수행한 자료를 도시한 도면,
도 5 내지 도 10은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물의 보습 평가를 실시한 실험결과를 나타낸 도면으로,
도 5 내지 도 7은 마그네슘트라이펩타이드-1이 첨가되지 않은 화장료 조성물의 보습평가를 실시한 실험결과이며,
도 8 내지 도 10은 본 발명에 따라 제조된 마그네슘트라이펩타이드-1이 첨가된 화장료 조성물의 보습평가를 실시한 실험결과이고,
도 11은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 첨가유무에 따른 토너의 수분도를 비교한 실험결과를 나타낸 도면이다. 1 is a flow chart of a method for producing magnesium tripeptide-1 according to a preferred embodiment of the present invention;
Figures 2 to 4 show data obtained by performing NMR analysis to analyze the molecular structure of magnesium tripeptide-1 and IR analysis to confirm functional group binding according to a preferred embodiment of the present invention;
Figures 5 to 10 are diagrams showing experimental results of moisturizing evaluation of a cosmetic composition containing magnesium tripeptide-1 according to a preferred embodiment of the present invention.
Figures 5 to 7 are the results of an experiment conducted on moisturizing evaluation of a cosmetic composition without added magnesium tripeptide-1;
Figures 8 to 10 are experimental results of moisturizing evaluation of the cosmetic composition to which magnesium tripeptide-1 prepared according to the present invention was added;
Figure 11 is a diagram showing the results of an experiment comparing the moisture content of toner with or without the addition of magnesium tripeptide-1 according to a preferred embodiment of the present invention.
이하, 본 발명의 바람직한 실시예를 첨부된 도면들을 참조하여 상세히 설명한다. 우선 각 도면의 구성 요소들에 참조 부호를 부가함에 있어서, 동일한 구성 요소들에 대해서는 비록 다른 도면상에 표시되더라도 가능한 한 동일한 부호를 가지도록 하고 있음에 유의해야 한다. 또한, 본 발명을 설명함에 있어, 관련된 공지 구성 또는 기능에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명은 생략한다. 또한, 이하에서 본 발명의 바람직한 실시예를 설명할 것이나, 본 발명의 기술적 사상은 이에 한정하거나 제한되지 않고 당업자에 의해 변형되어 다양하게 실시될 수 있음은 물론이다.Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the attached drawings. First, when adding reference signs to components in each drawing, it should be noted that the same components are given the same reference numerals as much as possible even if they are shown in different drawings. Additionally, in describing the present invention, if it is determined that a detailed description of a related known configuration or function may obscure the gist of the present invention, the detailed description will be omitted. In addition, preferred embodiments of the present invention will be described below, but the technical idea of the present invention is not limited or restricted thereto, and of course, it can be modified and implemented in various ways by those skilled in the art.
도 1은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1 제조방법의 순서도이고, 도 2 내지 도 4는 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 분자구조 분석을 위해 NMR 분석과 작용기 결합여부 확인을 위한 IR 분석을 수행한 자료를 도시한 도면이며, 도 5 내지 도 10은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물의 보습 평가를 실시한 실험결과를 나타낸 도면으로, 도 5 내지 도 7은 마그네슘트라이펩타이드-1이 첨가되지 않은 화장료 조성물의 보습평가를 실시한 실험결과이며, 도 8 내지 도 10은 본 발명에 따라 제조된 마그네슘트라이펩타이드-1이 첨가된 화장료 조성물의 보습평가를 실시한 실험결과이고, 도 11은 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 첨가유무에 따른 토너의 수분도를 비교한 실험결과를 나타낸 도면이다. Figure 1 is a flowchart of a method for producing magnesium tripeptide-1 according to a preferred embodiment of the present invention, and Figures 2 to 4 show NMR analysis and NMR analysis for molecular structure analysis of magnesium tripeptide-1 according to a preferred embodiment of the present invention. It is a diagram showing data obtained by performing IR analysis to confirm whether functional group is bound, and Figures 5 to 10 show the experimental results of moisturizing evaluation of a cosmetic composition containing magnesium tripeptide-1 according to a preferred embodiment of the present invention. In the drawings shown, Figures 5 to 7 are experimental results of moisturizing evaluation of cosmetic compositions to which magnesium tripeptide-1 was not added, and Figures 8 to 10 are to those to which magnesium tripeptide-1 prepared according to the present invention was added. This is an experimental result of moisturizing evaluation of a cosmetic composition, and Figure 11 is a diagram showing the experimental results comparing the moisture content of toner with or without the addition of magnesium tripeptide-1 according to a preferred embodiment of the present invention.
이하에서는, 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 제조방법을 설명한다. Below, a method for producing magnesium tripeptide-1 according to a preferred embodiment of the present invention will be described.
도 1을 참조하면, 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1의 제조방법은 트라이펩타이드-1 합성단계(S10), 마그네슘트라이펩타이드-1 합성단계(S20)를 포함하여 이루어진다. Referring to Figure 1, the method for producing magnesium tripeptide-1 according to a preferred embodiment of the present invention includes a tripeptide-1 synthesis step (S10) and a magnesium tripeptide-1 synthesis step (S20).
트라이펩타이드-1 합성단계(S10)는 L-아르기닌에 L(+)-아스파트산 및 L-글루탐산을 순차적으로 펩타이드반응을 수행하여 트라이펩타이드-1을 합성하는 과정이다.The tripeptide-1 synthesis step (S10) is a process of synthesizing tripeptide-1 by sequentially performing a peptide reaction of L-arginine with L(+)-aspartic acid and L-glutamic acid.
구체적으로, 트라이펩타이드-1 합성단계(S10)는 정제수에 L-아르기닌을 상온에서 완전 용해시킨 후 L(+)-아스파트산을 가하여 40℃에서 10분 간 가열 교반하여 펩타이드 반응을 수행하여 알지닌아스파테이트(Arginine Aspartate)를 합성하여 알지닌아스파테이트 수용액을 수득하는 제1 합성과정, 제1 합성과정을 거쳐 수득된 알지닌아스파테이트 수용액에 L-글루탐산을 가하고 60℃에서 30분 간 가열 교반하여 펩타이드 반응을 수행하여 트라이펩타이드-1(알지닌아스파테이트/글루타메이트)을 합성하여 트라이펩타이드-1 수용액을 수득하는 제2 합성과정을 포함한다. Specifically, in the tripeptide-1 synthesis step (S10), L-arginine is completely dissolved in purified water at room temperature, then L(+)-aspartic acid is added and heated and stirred at 40°C for 10 minutes to perform a peptide reaction. The first synthesis process of synthesizing arginine aspartate to obtain an aqueous arginine aspartate solution. Adding L-glutamic acid to the aqueous solution of arginine aspartate obtained through the first synthesis process and heating and stirring at 60°C for 30 minutes. It includes a second synthesis process of performing a peptide reaction to synthesize tripeptide-1 (arginine aspartate/glutamate) to obtain an aqueous solution of tripeptide-1.
트라이펩타이드-1 합성단계(S10)에서 반응온도는 40~60℃의 범위에서 이루어진다. 반응온도가 40℃ 미만일 경우, 반응 요구온도 미만으로써 반응이 수행되지 않고, 60℃ 초과일 경우, 이온화 반응 요구 수분량이 감소하여 반응 전환율이 감소하게 되는 단점이 있다. In the tripeptide-1 synthesis step (S10), the reaction temperature is in the range of 40 to 60°C. If the reaction temperature is less than 40°C, the reaction is not performed because it is less than the required reaction temperature, and if it is higher than 60°C, there is a disadvantage in that the amount of moisture required for the ionization reaction decreases and the reaction conversion rate decreases.
트라이펩타이드-1 합성단계(S10)에서 반응시간은 10~30분 간 이루어진다. In the tripeptide-1 synthesis step (S10), the reaction time is 10 to 30 minutes.
반응시간이 10분 미만일 경우, 반응 평형시간 미만으로써 반응이 완벽히 수행되지 않는 단점이 있고, 30분 초과일 경우, 반응 평형시간을 초과함으로써 유의적 효과가 없다. If the reaction time is less than 10 minutes, there is a disadvantage in that the reaction is not completely carried out because it is less than the reaction equilibrium time, and if it is more than 30 minutes, there is no significant effect because the reaction equilibrium time is exceeded.
마그네슘트라이펩타이드-1 합성단계(S20)는 트라이펩타이드-1 합성단계(S10)에서 합성된 트라이펩타이드-1에 마그네슘이온을 결합시켜 마그네슘트라이펩타이드-1을 합성하는 과정이다. The magnesium tripeptide-1 synthesis step (S20) is a process of synthesizing magnesium tripeptide-1 by binding magnesium ions to the tripeptide-1 synthesized in the tripeptide-1 synthesis step (S10).
구체적으로, 마그네슘트라이펩타이드-1 합성단계(S20)는 트라이펩타이드-1 합성단계(S10)를 거쳐 반응종료된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 55℃~100℃에서 20분~120분 간 가열 교반하여 마그네슘트라이펩타이드-1(마그네슘알지닌아스파테이트/글루타메이트)을 합성하여 마그네슘트라이펩타이드-1 수용액을 수득한다. Specifically, in the magnesium tripeptide-1 synthesis step (S20), magnesium hydroxide is added to the tripeptide-1 aqueous solution in which the reaction has been completed through the tripeptide-1 synthesis step (S10), and the reaction mixture is heated at 55°C to 100°C for 20 minutes to 120°C. Magnesium tripeptide-1 (magnesium arginine aspartate/glutamate) is synthesized by heating and stirring for several minutes to obtain an aqueous magnesium tripeptide-1 solution.
마그네슘트라이펩타이드-1 합성단계(S20)에서 반응온도는 55℃~100℃ 에서 이루어진다. 보다 바람직하게는 마그네슘트라이펩타이드-1 합성단계(S20)에서 반응온도는 80℃인 것으로 한다. In the magnesium tripeptide-1 synthesis step (S20), the reaction temperature is 55°C to 100°C. More preferably, the reaction temperature in the magnesium tripeptide-1 synthesis step (S20) is 80°C.
반응온도가 55℃ 미만일 경우, 반응 요구온도 미만으로써 반응이 수행되지 않고, 100℃ 초과일 경우, 탈수 축합 반응 속도는 급격히 증가하나, 탄화물 생성과 냄새 물질 생성을 동반하는 문제가 발생된다. If the reaction temperature is less than 55°C, the reaction is not performed because it is less than the required reaction temperature, and if it is more than 100°C, the dehydration condensation reaction rate increases rapidly, but problems such as the production of carbides and odorous substances occur.
마그네슘트라이펩타이드-1 합성단계(S20)에서 반응시간은 20분~120분 에서 이루어진다. In the magnesium tripeptide-1 synthesis step (S20), the reaction time is 20 to 120 minutes.
반응시간이 20분 미만일 경우에는 반응 평형시간 미만으로써 반응이 완벽히 수행되지 않으며, 120분 초과일 경우에는 반응평형시간을 초과함으로써 유의적 효과가 없다. If the reaction time is less than 20 minutes, the reaction is not completely performed because it is less than the reaction equilibrium time, and if it is longer than 120 minutes, there is no significant effect because it exceeds the reaction equilibrium time.
보다 바람직하게는 마그네슘트라이펩타이드-1 합성단계(S20)에서 반응시간은 30~60분인 것으로 한다. More preferably, the reaction time in the magnesium tripeptide-1 synthesis step (S20) is 30 to 60 minutes.
이하, 화학식 1은 상기 트라이펩타이드-1 합성단계, 마그네슘트라이펩타이드-1 합성단계를 거쳐 제조된 마그네슘트라이펩타이드-1의 분자 구조식을 나타낸 것이다.Hereinafter, Chemical Formula 1 shows the molecular structural formula of magnesium tripeptide-1 prepared through the above tripeptide-1 synthesis step and magnesium tripeptide-1 synthesis step.
이하는, 상기 트라이펩타이드-1 합성단계, 마그네슘트라이펩타이드-1 합성단계를 거쳐 제조된 마그네슘트라이펩타이드-1의 합성 메커니즘을 나타낸 것이다. The following shows the synthesis mechanism of magnesium tripeptide-1 prepared through the above tripeptide-1 synthesis step and magnesium tripeptide-1 synthesis step.
도 2 내지 도 4는 트라이펩타이드-1 합성단계(S10), 마그네슘트라이펩타이드-1 합성단계(S20)를 거쳐 합성된 마그네슘트라이펩타이드-1의 분자구조 분석을 위해 NMR 분석과 작용기 결합여부 확인을 위한 IR 분석을 수행한 자료이다. Figures 2 to 4 show NMR analysis for molecular structure analysis of magnesium tripeptide-1 synthesized through the tripeptide-1 synthesis step (S10) and the magnesium tripeptide-1 synthesis step (S20) and confirmation of functional group binding. This is data from which IR analysis was performed.
이하, 본 발명의 이해를 돕기 위하여 실시 예를 제시하나, 하기 실시 예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시 예에 한정되는 것은 아니다. Hereinafter, examples will be presented to aid understanding of the present invention. However, the following examples are merely illustrative of the present invention and the scope of the present invention is not limited to the following examples.
먼저, L-아르기닌 174g을 정제수 966g에 상온에서 완전 용해시킨 후 L(+)-아스파트산 133g을 가하여 40℃에서 10분 간 가열 교반하여 펩타이드 반응을 수행하여 알지닌아스파테이트를 합성한다. 이후, 상기 반응종료된 알지닌아스파테이트 수용액에 L-글루탐산 147g을 가하고, 60℃에서 30분 간 가열 교반하여 펩타이드 반응을 수행하여 트라이펩타이드-1(알지닌아스파테이트/글루타메이트)를 합성한다. First, 174 g of L-arginine was completely dissolved in 966 g of purified water at room temperature, then 133 g of L(+)-aspartic acid was added and heated and stirred at 40°C for 10 minutes to perform a peptide reaction to synthesize arginine aspartate. Afterwards, 147 g of L-glutamic acid was added to the arginine aspartate aqueous solution where the reaction was completed, and the mixture was heated and stirred at 60°C for 30 minutes to perform a peptide reaction to synthesize tripeptide-1 (arginine aspartate/glutamate).
상기 반응 종료된 트라이펩타이드-1 수용액에 수산화마그네슘 29g을 첨가하고 80℃에서 60분 간 가열 교반하여 마그네슘트라이펩타이드-1(마그네슘알지닌아스파테이트/글루타메이트)을 합성하여 30.12 농도%의 마그네슘트라이펩타이드-1 수용액을 수득한다. 29 g of magnesium hydroxide was added to the tripeptide-1 aqueous solution after the reaction was completed, heated and stirred at 80°C for 60 minutes to synthesize magnesium tripeptide-1 (magnesium arginine aspartate/glutamate), and magnesium tripeptide-1 with a concentration of 30.12% was obtained. 1 Obtain an aqueous solution.
(실시예 1) 마그네슘트라이펩타이드-1을 포함하는 토너 조성물의 제조(Example 1) Preparation of toner composition containing magnesium tripeptide-1
용매(정제수 92.53g)에 보습제(마그네슘트라이펩타이드-1 3g, 글리세린 1g, 1,3-부틸렌글라이콜 0.5g, 1,2-헥산다이올 2g, 히알루론산 0.1g, 자일리톨 0.1g, 베타인 0.1g, 알로에베라 추출물 0.5g, 하이드로식물성단백질 0.1g, 말토덱스트린 0.01g)을 60℃ 내지 70℃에서 10분간 가온 교반하여 완전 용해한다. 이후, 상기 반응종료된 용액에 pH 조절제(구연산 0.01g) 및 가용화제(폴리글리세릴-10 라우레이트 0.05g)을 가하고 60℃ 내지 70℃에서 가온 교반하여 마그네슘트라이펩타이드-1을 포함하는 토너 조성물을 제조하였다. Solvent (purified water 92.53g) and moisturizer (magnesium tripeptide-1 3g, glycerin 1g, 1,3-butylene glycol 0.5g, 1,2-hexanediol 2g, hyaluronic acid 0.1g, xylitol 0.1g, betaine 0.1 g, 0.5 g of aloe vera extract, 0.1 g of hydrovegetable protein, and 0.01 g of maltodextrin) are completely dissolved by heating and stirring at 60°C to 70°C for 10 minutes. Afterwards, a pH adjuster (0.01 g of citric acid) and a solubilizer (0.05 g of polyglyceryl-10 laurate) were added to the reaction solution, and the mixture was heated and stirred at 60°C to 70°C to prepare a toner composition containing magnesium tripeptide-1. was manufactured.
(실시예 2) 마그네슘트라이펩타이드-1을 포함하는 마스크팩 조성물의 제조(Example 2) Preparation of a mask pack composition containing magnesium tripeptide-1
점도증가제(잔탄검 0.3g, 하이드록시프로필스타치포스페이트 1g)에 보습제(글리세린 5g)을 가하여 완전 분산한 후 정제수 65.79g을 투입한 후 70℃ 내지 80℃에서 30분간 가온 교반한 후, 세포외 보습인자인 마그네슘트라이펩타이드-1 3g, 및 산화방지제(마그네슘아스코빌포스페이트) 0.01g을 가하여 70℃에서 10분간 가열 교반하여 수상을 제조한다. 여기에, 호모믹서를 이용하여 3,000rpm 내지 4,000rpm의 회전속도로 교반을 유지한 상태에서, 피부컨디셔닝제(카프릴릭/카프릭 트리글리세라이드 3g, 시어버터 3g, 마카다미아씨 오일 3g, 정제올리브오일 3g), 유화제(폴리글리세릴-3 메틸글루코오스디스테아레이트 3g, 글리세릴스테아레이트&피이지-100스테아레이트 2g, 세틸알코올 3g, 스테아릭산 2g), 산화방지제(토코페릴 아세테이트 0.3g), 착향제(오렌지껍질오일 1g), 보존제(에틸헥실글리세린 0.6g)을 칭량하여 80℃ 내지 90℃에서 가온하여 완전 용해시킨 후 호모믹서로 교반 중인 수상에 가하여 10분간 3,000rpm 내지 4,000rpm의 회전속도로 교반하며 냉각시킨다. 50℃ 이하까지 냉각한 후 다이메치콘 1g을 가하여 3,000rpm 내지 4,000rpm의 속도로 10분간 교반한 후 마그네슘트라이펩타이드-1을 포함하는 마스크팩 조성물을 제조한다. After adding a humectant (5 g of glycerin) to the viscosity increasing agent (0.3 g of xanthan gum, 1 g of hydroxypropyl starch phosphate) and completely dispersing it, 65.79 g of purified water was added, and the cells were heated and stirred at 70°C to 80°C for 30 minutes. Add 3g of magnesium tripeptide-1, an external moisturizing factor, and 0.01g of antioxidant (magnesium ascorbyl phosphate), and heat and stir at 70°C for 10 minutes to prepare an aqueous phase. Here, while maintaining stirring at a rotation speed of 3,000 rpm to 4,000 rpm using a homomixer, skin conditioning agent (3g caprylic/capric triglyceride, 3g shea butter, 3g macadamia seed oil, refined olive oil) 3g), emulsifier (polyglyceryl-3 methylglucose distearate 3g, glyceryl stearate & PEG-100 stearate 2g, cetyl alcohol 3g, stearic acid 2g), antioxidant (tocopheryl acetate 0.3g), complex Weigh the flavoring agent (1 g of orange peel oil) and the preservative (0.6 g of ethylhexyl glycerin) and heat at 80°C to 90°C to completely dissolve them, then add them to the aqueous phase being stirred with a homomixer and mix at a rotation speed of 3,000 rpm to 4,000 rpm for 10 minutes. Stir and cool. After cooling to 50°C or lower, 1 g of dimethicone was added and stirred for 10 minutes at a speed of 3,000 rpm to 4,000 rpm to prepare a mask pack composition containing magnesium tripeptide-1.
(실시예 3) 마그네슘트라이펩타이드-1을 포함하는 로션 조성물의 제조(Example 3) Preparation of lotion composition containing magnesium tripeptide-1
점도증가제(소듐폴리아크릴로일다이메틸타우레이트/하이드로제네이티드폴리데센/트라이데세스-10 0.3g)에 보습제(글리세린 10g, 1,3-부틸렌글라이콜 3g, 1,2-헥산다이올 2g)을 가하여 완전 분산한 후 정제수 72.1g을 투입한 후 70℃ 내지 80℃에서 30분간 가온 교반한 후, 세포외 보습인자인 마그네슘트라이펩타이드-1 3g을 가하여 70℃에서 10분간 가열 교반하여 수상을 제조한다. 여기에 호모믹서를 이용하여 3,000rpm 내지 4,000rpm의 회전속도로 교반을 유지한 상태에서, 유화제(폴리글리세릴-3메틸글루코오스디스테아레이트 3g, 세테아릴 알코올 2g, 글리세릴스테아레이트 2g, 세틸알코올 2g) 및 피부컨디셔닝제(마카다미아씨 오일 1g), 보존제(에틸헥실글리세린 0.6g)를 칭량하여 80℃ 내지 90℃에서 가온하여 완전 용해시킨 후 호모믹서로 교반 중인 수상에 가하여 10분간 3,000rpm 내지 4,000rpm 의 회전속도로 교반하며 냉각시켜 마그네슘트라이펩타이드-1을 포함하는 로션 조성물을 제조한다. Viscosity increasing agent (sodium polyacryloyldimethyl taurate/hydrogenated polydecene/trideceth-10 0.3g) and moisturizer (glycerin 10g, 1,3-butylene glycol 3g, 1,2-hexanedimethylsiloxane) After adding and completely dispersing 72.1g of purified water, heating and stirring at 70°C to 80°C for 30 minutes, 3g of magnesium tripeptide-1, an extracellular moisturizing factor, was added, heating and stirring at 70°C for 10 minutes. manufactures awards. Here, while maintaining stirring at a rotation speed of 3,000 rpm to 4,000 rpm using a homomixer, an emulsifier (3 g of polyglyceryl-3methylglucose distearate, 2 g of cetearyl alcohol, 2 g of glyceryl stearate, and cetyl Weigh the alcohol (2g alcohol), skin conditioning agent (macadamia seed oil 1g), and preservative (0.6g ethylhexylglycerin) and heat at 80°C to 90°C to completely dissolve, then add to the aqueous phase being stirred with a homomixer and mix at 3,000rpm for 10 minutes. A lotion composition containing magnesium tripeptide-1 is prepared by stirring and cooling at a rotation speed of 4,000 rpm.
(실시예 4) 마그네슘트라이펩타이드-1을 포함하는 크림 조성물의 제조(Example 4) Preparation of cream composition containing magnesium tripeptide-1
점도증가제(소듐폴리아크릴로일다이메틸타우레이트/하이드로제네이티드폴리데센/트라이데세스-10) 1g에 보습제(글리세린 15g, 1,3-부틸렌글라이콜 3g, 1,2-헥산다이올 2g)을 가하여 완전 분산한 후 정제수 62g을 투입한 후 70℃ 내지 80℃에서 30분간 가온 교반한 후, 세포외 보습인자인 마그네슘트라이펩타이드-1 1g 을 가하여 70℃에서 10분간 가열 교반하여 수상을 제조하였다. 여기에 호모믹서를 이용하여 3,000rpm 내지 4,000rpm의 회전속도로 교반을 유지한 상태에서, 유화제(폴리글리세릴-3메틸글루코오스디스테아레이트 3g, 세테아릴 알코올 2g, 폴리솔베이트60 2g) 및 피부컨디셔닝제(프로필렌글라이콜다이카프릴레이트/다이카프레이트 5g)를 칭량하여 80℃ 내지 90℃에서 가온하여 완전 용해시킨 후 호모믹서로 교반중인 수상에 가하여 10분간 3,000rpm 내지 4,000rpm의 회전속도로 교반하며 냉각시켜 마그네슘트라이펩타이드-1을 포함하는 크림 조성물을 제조한다. 1g of viscosity increasing agent (sodium polyacryloyldimethyl taurate/hydrogenated polydecene/trideceth-10) and moisturizer (15g of glycerin, 3g of 1,3-butylene glycol, 1,2-hexanediol) 2g) was added and completely dispersed, then 62g of purified water was added, heated and stirred at 70°C to 80°C for 30 minutes, then 1g of magnesium tripeptide-1, an extracellular moisturizing factor, was added and heated and stirred at 70°C for 10 minutes to form an aqueous phase. Manufactured. Here, while maintaining stirring at a rotation speed of 3,000 rpm to 4,000 rpm using a homomixer, an emulsifier (3 g of polyglyceryl-3methylglucose distearate, 2 g of cetearyl alcohol, 2 g of polysorbate 60) and Weigh the skin conditioning agent (5g of propylene glycol dicaprylate/dicaprate) and heat it at 80°C to 90°C to completely dissolve it, then add it to the aqueous phase being stirred with a homomixer and rotate at 3,000rpm to 4,000rpm for 10 minutes. A cream composition containing magnesium tripeptide-1 is prepared by stirring at high speed and cooling.
이하, 표 1은 본 발명의 바람직한 실시예에 따라 제조된 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물 중 토너의 성분과 조성함량, 각 성분의 용도를 도식화한 것이다. Table 1 below schematically illustrates the toner components, composition content, and use of each component in the cosmetic composition containing magnesium tripeptide-1 prepared according to a preferred embodiment of the present invention.
이하, 표 2는 본 발명의 바람직한 실시예에 따라 제조된 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물 중 마스크팩의 성분과 조성함량, 각 성분의 용도를 도식화한 것이다. Table 2 below schematically illustrates the ingredients and composition content of the mask pack and the use of each ingredient in the cosmetic composition containing magnesium tripeptide-1 prepared according to a preferred embodiment of the present invention.
스테아레이트Glyceryl Stearate & PEG-100
stearate
이하, 표 3은 본 발명의 바람직한 실시예에 따라 제조된 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물 중 로션의 성분과 조성함량, 각 성분의 용도를 도식화한 것이다. Table 3 below schematically illustrates the ingredients and composition content of the lotion and the use of each ingredient in the cosmetic composition containing magnesium tripeptide-1 prepared according to a preferred embodiment of the present invention.
이하, 표 4는 본 발명의 바람직한 실시예에 따라 제조된 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물 중 크림의 성분과 조성함량, 각 성분의 용도를 도식화한 것이다. Table 4 below schematically illustrates the ingredients and composition content of the cream and the use of each ingredient in the cosmetic composition containing magnesium tripeptide-1 prepared according to a preferred embodiment of the present invention.
이하, 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1 을 함유하는 화장료 조성물의 보습평가를 실시하였다. Hereinafter, a moisturizing evaluation was performed on a cosmetic composition containing magnesium tripeptide-1 according to a preferred embodiment of the present invention.
실험기구는 피부진단기(아로 아람휴비스(ASW-100))을 이용하였으며, 평가항목은 수분이며, 마그네슘 트라이펩타이드-1이 첨가된 토너와 마그네슘 트라이펩타이드-1이 첨가되지 않은 토너의 보습평가를 실시한다. The experimental device used was a skin diagnosis device (Aro Aram Huvis (ASW-100)), and the evaluation item was moisture. Moisturizing evaluation was conducted on toner with magnesium tripeptide-1 and toner without magnesium tripeptide-1. do.
마그네슘트라이펩타이드-1이 함유된 토너는 마그네슘트라이펩타이드-1 3중량%, 글리세린 1중량%, 1,3-부틸렌글라이콜 0.5중량%, 1,2-헥산다이올 2중량%, 히알루론산 0.1중량%, 자일리톨 0.1중량%, 베타인 0.1중량%, 알로에베라 추출물 0.5중량%, 하이드로 식물성단백질 0.1중량%, 말토 덱스트린 0.01중량%, 구연산 0.01중량%, 폴리글리세릴-10 라우레이트 0.05중량%, 정제수 92.53중량%로 구성된다. Toner containing magnesium tripeptide-1 is 3% by weight of magnesium tripeptide-1, 1% by weight of glycerin, 0.5% by weight of 1,3-butylene glycol, 2% by weight of 1,2-hexanediol, and 0.1% by weight of hyaluronic acid. Weight %, xylitol 0.1% by weight, betaine 0.1% by weight, aloe vera extract 0.5% by weight, hydro vegetable protein 0.1% by weight, maltodextrin 0.01% by weight, citric acid 0.01% by weight, polyglyceryl-10 laurate 0.05% by weight, It consists of 92.53% by weight of purified water.
마그네슘트라이펩타이드-1이 함유되지 않은 토너는 글리세린 1중량%, 1,3-부틸렌글라이콜 0.5중량%, 1,2-헥산다이올 2중량%, 히알루론산 0.1중량%, 자일리톨 0.1중량%, 베타인 0.1중량%, 알로에베라 추출물 0.5중량%, 하이드로 식물성단백질 0.1중량%, 말토 덱스트린 0.01중량%, 구연산 0.01중량%, 폴리글리세릴-10 라우레이트 0.05중량%, 정제수 95.53중량%로 구성된다. Toner that does not contain magnesium tripeptide-1 contains 1% by weight of glycerin, 0.5% by weight of 1,3-butylene glycol, 2% by weight of 1,2-hexanediol, 0.1% by weight of hyaluronic acid, 0.1% by weight of xylitol, It consists of 0.1% by weight of betaine, 0.5% by weight of aloe vera extract, 0.1% by weight of hydro vegetable protein, 0.01% by weight of maltodextrin, 0.01% by weight of citric acid, 0.05% by weight of polyglyceryl-10 laurate, and 95.53% by weight of purified water.
먼저, 마그네슘 트라이펩타이드-1이 함유되지 않은 토너의 수분력을 측정한다. 20대 남성(이하, 피실험자)의 오른쪽 손등에 마그네슘 트라이펩타이드-1이 함유되지 않은 토너를 도포한다. First, measure the moisture power of a toner that does not contain magnesium tripeptide-1. A toner containing no magnesium tripeptide-1 was applied to the back of the right hand of a man in his 20s (hereinafter referred to as the test subject).
도 5는 도포 전 피실험자의 오른손의 수분측정함량을 나타낸 것으로, 도포 전 오른손의 수분측정함량은 10으로 나타났다.Figure 5 shows the measured moisture content of the subject's right hand before application, and the measured moisture content of the right hand before application was found to be 10.
도 6은 도포 직후, 피실험자의 오른손의 수분측정함량을 나타낸 것으로, 도포 직후 수분측정함량은 46으로 나타났으며, 도 7은 도포 30분 후, 피실험자의 오른손의 수분측정함량을 나타낸 것으로, 도포 30분 후 수분측정함량은 32로 나타났다. Figure 6 shows the measured moisture content of the subject's right hand immediately after application, and the measured moisture content immediately after application was found to be 46. Figure 7 shows the measured moisture content of the subject's right hand 30 minutes after application, showing the measured moisture content of the subject's right hand 30 minutes after application. Minutes later, the moisture content was found to be 32.
다음으로, 마그네슘 트라이펩타이드-1이 함유된 토너의 수분력을 측정한다. 20대 남성(이하, 피실험자)의 왼쪽 손등에 마그네슘 트라이펩타이드-1이 함유된 토너를 도포한다. Next, measure the moisture power of the toner containing magnesium tripeptide-1. A toner containing magnesium tripeptide-1 was applied to the back of the left hand of a man in his 20s (hereinafter referred to as the test subject).
도 8은 도포 전 피실험자의 왼손의 수분측정함량을 나타낸 것으로, 도포 전 왼손의 수분측정함량은 6으로 나타났다. Figure 8 shows the measured moisture content of the subject's left hand before application, and the measured moisture content of the left hand before application was found to be 6.
도 9는 도포 직후, 왼손의 수분측정함량은 69로 나타났으며, 도 10은 도포 30분 후, 피실험자의 왼손의 수분측정함량을 나타낸 것으로, 도포 30분 후 수분측정함량은 53으로 나타났다. Figure 9 shows the measured moisture content of the left hand immediately after application, and Figure 10 shows the measured moisture content of the subject's left hand 30 minutes after application, and the measured moisture content 30 minutes after application was found to be 53.
상기 결과를 살펴보면, 본 발명에 따른 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물을 도포하였을 때가 마그네슘트라이펩타이드-1을 포함하지 않은 화장료 조성물에 비해 피부 보습력이 향상되었음을 확인하였다. Looking at the above results, it was confirmed that when the cosmetic composition containing magnesium tripeptide-1 according to the present invention was applied, skin moisturizing power was improved compared to the cosmetic composition that did not contain magnesium tripeptide-1.
또한, 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물은 피부진정, 피부장벽 강화, 경피수분손실량 감소, 손살 각질층의 정상화 등의 효과를 기대할 수 있다. In addition, the cosmetic composition containing magnesium tripeptide-1 according to a preferred embodiment of the present invention can be expected to have effects such as soothing the skin, strengthening the skin barrier, reducing transepidermal water loss, and normalizing the keratin layer of the hand.
또한, 본 발명의 바람직한 실시예에 따른 마그네슘트라이펩타이드-1을 포함하는 화장료 조성물은 사용 시 끈적임을 유발하지 않으며, 화장품 조성 내 기타 피부 보습제와 동반 사용 시 피부 밀착감을 증대시킬 수 있어 보습 유지력의 향상에 효과적일 것으로 기대된다. In addition, the cosmetic composition containing magnesium tripeptide-1 according to a preferred embodiment of the present invention does not cause stickiness when used, and can increase skin adhesion when used together with other skin moisturizers in the cosmetic composition, thereby improving moisture retention. It is expected to be effective.
이상의 설명은 본 발명의 기술 사상을 예시적으로 설명한 것에 불과한 것으로서, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위 내에서 다양한 수정, 변경 및 치환이 가능할 것이다. 따라서, 본 발명에 개시된 실시예 및 첨부된 도면들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시예 및 첨부된 도면에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다. 본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.The above description is merely an illustrative explanation of the technical idea of the present invention, and various modifications, changes, and substitutions can be made by those skilled in the art without departing from the essential characteristics of the present invention. will be. Accordingly, the embodiments disclosed in the present invention and the attached drawings are not intended to limit the technical idea of the present invention, but are for illustrative purposes, and the scope of the technical idea of the present invention is not limited by these embodiments and the attached drawings. . The scope of protection of the present invention should be interpreted in accordance with the claims below, and all technical ideas within the equivalent scope should be construed as being included in the scope of rights of the present invention.
S10 - 트라이펩타이드-1 합성
S20 - 마그네슘트라이펩타이드-1 합성S10 - Tripeptide-1 synthesis
S20 - Magnesium tripeptide-1 synthesis
Claims (3)
(b) 트라이펩타이드-1 합성단계를 거쳐 반응종료된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 가열 교반하여 마그네슘트라이펩타이드-1 수용액을 수득하는 마그네슘트라이펩타이드-1 합성단계
를 포함하는 마그네슘트라이펩타이드-1의 제조방법. (a) A first synthesis process in which L-arginine is completely dissolved in purified water at room temperature, then L(+)-aspartic acid is added and heated and stirred to perform a peptide reaction to obtain an aqueous arginine aspartate solution. A tripeptide-1 synthesis process including a second process of adding L-glutamic acid to the arginine aspartate aqueous solution obtained through heating and stirring to perform a peptide reaction to obtain a tripeptide-1 aqueous solution;
(b) Magnesium tripeptide-1 synthesis step of adding magnesium hydroxide to the tripeptide-1 aqueous solution that has completed the reaction through the tripeptide-1 synthesis step and heating and stirring to obtain a magnesium tripeptide-1 aqueous solution.
Method for producing magnesium tripeptide-1 comprising.
(a) 단계에서는
제1 합성과정에서 L-아르기닌을 정제수에 상온에서 완전 용해시킨 후 L(+)-아스파트산을 가하여 40℃에서 10분 간 가열 교반하여 펩타이드 반응을 수행하고,
제2 합성과정에서는 제1 합성과정을 거쳐 수득된 알지닌아스파테이트 수용액에 L-글루탐산을 가하고 60℃에서 30분 간 가열 교반하여 펩타이드 반응을 수행하는 것
을 포함하는 마그네슘트라이펩타이드-1의 제조방법. According to paragraph 1,
In step (a)
In the first synthesis process, L-arginine is completely dissolved in purified water at room temperature, then L(+)-aspartic acid is added and heated and stirred at 40°C for 10 minutes to perform a peptide reaction.
In the second synthesis process, L-glutamic acid is added to the arginine aspartate aqueous solution obtained through the first synthesis process, and the peptide reaction is performed by heating and stirring at 60°C for 30 minutes.
Method for producing magnesium tripeptide-1 comprising.
(b) 단계에서는
상기 (a) 단계를 거쳐 수득된 트라이펩타이드-1 수용액에 수산화마그네슘을 첨가하고, 55℃~100℃ 에서 30분~60분 간 가열 교반하는 것
을 특징으로 하는 마그네슘트라이펩타이드-1의 제조방법.
According to paragraph 1,
In step (b)
Add magnesium hydroxide to the aqueous solution of tripeptide-1 obtained through step (a), heat and stir at 55°C to 100°C for 30 to 60 minutes.
A method for producing magnesium tripeptide-1, characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240005910A KR102652375B1 (en) | 2024-01-15 | 2024-01-15 | Method for producing magnesium tripeptide-1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240005910A KR102652375B1 (en) | 2024-01-15 | 2024-01-15 | Method for producing magnesium tripeptide-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102652375B1 true KR102652375B1 (en) | 2024-03-28 |
Family
ID=90482655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020240005910A KR102652375B1 (en) | 2024-01-15 | 2024-01-15 | Method for producing magnesium tripeptide-1 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102652375B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102094220B1 (en) * | 2018-11-21 | 2020-03-30 | 주식회사 에스스킨 | Cyclic tripeptide, preparing method of the same, and composition for skin-whitening including the same |
| CN111004306A (en) * | 2019-12-31 | 2020-04-14 | 山东济肽生物科技有限公司 | Liquid phase synthesis method of palmitoyl tripeptide-5 |
| KR20200127075A (en) * | 2019-04-30 | 2020-11-10 | 주식회사 바이오에프디엔씨 | A cosmetic composition for improving skin condition comprising functional lipopeptides |
-
2024
- 2024-01-15 KR KR1020240005910A patent/KR102652375B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102094220B1 (en) * | 2018-11-21 | 2020-03-30 | 주식회사 에스스킨 | Cyclic tripeptide, preparing method of the same, and composition for skin-whitening including the same |
| KR20200127075A (en) * | 2019-04-30 | 2020-11-10 | 주식회사 바이오에프디엔씨 | A cosmetic composition for improving skin condition comprising functional lipopeptides |
| CN111004306A (en) * | 2019-12-31 | 2020-04-14 | 山东济肽生物科技有限公司 | Liquid phase synthesis method of palmitoyl tripeptide-5 |
Non-Patent Citations (1)
| Title |
|---|
| CASE ET AL., ACS OMEGA 2021, 6(49), PP.33454~33461, 2021.11.30 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6608561B2 (en) | Skin care cosmetic composition | |
| CN109157453B (en) | Skin-friendly sustained-release composition and cosmetic thereof | |
| CN111166683A (en) | Fullerene anti-aging antioxidant beauty and skin care cosmetic and preparation method thereof | |
| CN111297745A (en) | Absorption-promoting whitening composition and production process and application thereof | |
| CN111450003A (en) | Anti-aging and beautifying nutrient containing golden fragrant willow extract, preparation method thereof, essence and extraction method of golden fragrant willow extract | |
| CN110960458A (en) | Moisturizing essence emulsion and preparation method thereof | |
| CN114983840A (en) | Skin barrier repairing composition capable of resisting external stimulation | |
| JP3922311B2 (en) | Skin aging prevention cosmetics | |
| KR101803271B1 (en) | Cosmetic composition for moisturizing or improving skin elasticity | |
| KR102233140B1 (en) | Cosmetic composition for skin improvement containing low molecular weight hyaluronic acid | |
| JP5504389B2 (en) | Skin moisturizer | |
| JP4088497B2 (en) | Cosmetics | |
| CN111821219A (en) | Composition with moisturizing effect and application thereof | |
| KR20190075186A (en) | Cosmetic Composition Containing Cholesteric Liquid Crystal With Dual Capsule Process | |
| KR101605324B1 (en) | Cosmetic composition for moisturizing skin which alleviates itchiness and dryness by removing keratin and increasing moisture | |
| US20080260675A1 (en) | Depolymerized Scleroglucan for Regulating and Improving the Moisture Content of the Skin | |
| KR102652375B1 (en) | Method for producing magnesium tripeptide-1 | |
| KR20110052095A (en) | Cosmetic composition for moisturizing of skin containing tremella fuciformis extracts | |
| JPH08268859A (en) | Cosmetic for preventing and improving wrinkle | |
| KR102247589B1 (en) | Cosmetic composition for improving skin comprising the moluccella laevis extraction and the hololeion maximowiczii Kitam. extraction as an effective ingredient | |
| KR101154772B1 (en) | Cosmetic composition containing the zizyphus jujuba fruit extract and walnut extract for moisturizing effect on the skin | |
| CN114948780A (en) | Long-acting soothing repair essence composition and preparation method thereof | |
| CN116546966A (en) | Method for producing a cosmetic composition comprising sucrose esters and a solvent | |
| JP5450918B2 (en) | Topical skin preparation | |
| KR102513929B1 (en) | Functional comsmetics materials having composition and composition ratio for skin elasticity, Manufacturing method thereof and Comsmetics for skin care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |